Evidence map›Paper›PMID 41073853›Full record

ArticleMikrochimica acta2025

All-trans-retinal as a modulator of metabolic and mitochondrial signatures in non-tumorigenic and malignant breast cells: a Raman-based approach.

Karolina Jarczewska, Monika Kopeć, Jakub Maciej Surmacki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Karolina JarczewskaLaboratory of Laser Molecular Spectroscopy, Institute of Applied Radiation Chemistry, Faculty of Chemistry, Lodz University of Technology, Wroblewskiego 15, 93-590, Lodz, Poland.ORCID 0000-0003-4270-4981
Monika KopećLaboratory of Laser Molecular Spectroscopy, Institute of Applied Radiation Chemistry, Faculty of Chemistry, Lodz University of Technology, Wroblewskiego 15, 93-590, Lodz, Poland.ORCID 0000-0001-5412-0399
Jakub Maciej SurmackiLaboratory of Laser Molecular Spectroscopy, Institute of Applied Radiation Chemistry, Faculty of Chemistry, Lodz University of Technology, Wroblewskiego 15, 93-590, Lodz, Poland. jakub.surmacki@p.lodz.pl.ORCID 0000-0001-6654-0286

Funding

Politechnika Lódzka FU2N 503/3-34-4-1
6 · The paper itself

Abstract

Retinoids are well recognized for their therapeutic potential in pharmacy and medicine. Although extensively studied for their anticancer properties, the specific effects of all-trans-retinal (ALTR) on the metabolism of breast cancer cells-particularly in relation to dose, incubation time, and tumour aggressiveness-remain insufficiently understood. In this study, the metabolic impact of ALTR on non-tumorigenic (MCF10A) and malignant breast cell lines (MCF7, MDA-MB-231) using Raman imaging and biological viability assays (XTT) were examined. Cells were incubated with 1 and 10 µM concentrations of ALTR for 24 and 48 h. Raman spectroscopy and imaging enabled both qualitative and quantitative detection of cellular organelles, allowing us to track ALTR-associated metabolic changes at the subcellular level. Our findings demonstrate that ALTR significantly reduced cell viability, particularly in cancerous lines, while promoting cellular development in non-tumorigenic MCF10A cells. Notably, a Raman band at 1597 cm

Indexed as

Breast NeoplasmsMitochondriaRetinaldehydeCell Line, TumorCell SurvivalFemaleHumansMCF-7 CellsSpectrum Analysis, RamanRetinaldehydeAll-trans-retinalBreast cancerCancer cell phenotypingRaman imagingRaman spectroscopy

Identifiers

PMID41073853
PMCPMC12513894

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.